Retrophin, Inc. announced that the FDA has approved 100 mg and 300 mg tablets of Thiola EC (tiopronin), a new...
The European Commission (EC) has granted marketing authorization for Inlyta (axitinib) from Pfizer for the treatment of adult patients with...
Astellas Pharma Europe has filed EC 905 its fixed dose combination of Flomaxtra XL (tamsulosin) and Vesicare(solifenacin)in the Netherlands under...
The European Commission (EC) has granted marketing authorization for Envarsus (tacrolimus once daily), from Veloxis Pharmaceuticals, for the prevention of...
AstraZeneca announced that the European Commission (EC) has on 6 December 2013 granted Marketing Authorisation to Fluenz Tetra. Fluenz Tetra...
The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen...
MHRA Explanatory Note: For a period of two years from 1 January 2021, when determining an application for a Great Britain Marketing Authorisations (MA), the MHRA may rely on a decision taken by the European Commission (EC) on the approval of a new MA in the centralised procedure.
Bristol-Myers Squibb Company announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment...
The European Commission has approved amendment of product information for Erbitux (cetuximab), from Merck Serono, updating the indication to the...